Jones R N
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City 52242.
Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):188-94. doi: 10.1007/BF01967076.
Compound E-4695, a C-7 azetidinyl fluoro-naphthyridine, was compared to six structurally related quinolones and was generally two- to four-fold more active than ciprofloxacin. E-4695 was particularly active against Staphylococcus aureus (MIC90 0.06 mg/l), Staphylococcus haemolyticus (MIC90 0.5 mg/l), Klebsiella spp. (MIC90 less than or equal to 0.015 mg/l), Serratia marcescens (MIC90 0.06 mg/l), Acinetobacter spp. (MIC90 less than or equal to 0.015 mg/l), Pseudomonas aeruginosa (MIC90 0.5 mg/l), Xanthomonas maltophilia (MIC90 0.5 mg/l), and Neisseria gonorrhoeae (MIC90 less than or equal to 0.001 mg/l). This new quinolone-like drug requires further investigations to confirm these promising in vitro findings.
化合物E - 4695,一种C - 7氮杂环丁烷基氟代萘啶,与六种结构相关的喹诺酮类药物进行了比较,其活性通常比环丙沙星高两到四倍。E - 4695对金黄色葡萄球菌(MIC90为0.06毫克/升)、溶血葡萄球菌(MIC90为0.5毫克/升)、克雷伯菌属(MIC90小于或等于0.015毫克/升)、粘质沙雷氏菌(MIC90为0.06毫克/升)、不动杆菌属(MIC90小于或等于0.015毫克/升)、铜绿假单胞菌(MIC90为0.5毫克/升)、嗜麦芽窄食单胞菌(MIC90为0.5毫克/升)和淋病奈瑟菌(MIC90小于或等于0.001毫克/升)具有特别强的活性。这种新型喹诺酮类药物需要进一步研究以证实这些有前景的体外研究结果。